Year: 2026
Type: article
Abstract: The Food and Drug Administration (FDA) on Jan. 12 announced its approval of the first prescription, physician‐directed, at‐home brain neuromodulation therapy as an adjunctive treatment for adults with major depressive disorder (MDD) who failed to achieve satisfactory improvement from at least one previous antidepressant.
Source: Mental Health Weekly
DOI: 10.1002/mhw.34723
Author: Valerie A. Canady
Language: English
Subfield: Neurology
Field: Neuroscience
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W7124443634
FWCI:
Cites:
Cited by:
Related to: